ARMATA PHARMACEUTICALS, INC. Business Combination, Contingent Consideration, Liability, Current
ARMATA PHARMACEUTICALS, INC. (ARMP) had Business Combination, Contingent Consideration, Liability, Current of $1.94 million as of 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2022-03-17
- 2020-12-31: Business Combination, Contingent Consideration, Liability, Current $1.94M.
- 2020-09-30: Business Combination, Contingent Consideration, Liability, Current $1.77M.
- 2020-06-30: Business Combination, Contingent Consideration, Liability, Current $1.62M.
- 2020-03-31: Business Combination, Contingent Consideration, Liability, Current $1.48M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2020-12-31 | $1.94M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.77M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.62M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $1.48M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $970.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $885.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $769.00K 10-Q · filed 2019-08-14 |
| 2018-12-31 | $970.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |